Symphogen Receives Milestone Payment from Genentech for Initiation of Phase 1 Clinical Trial Candidate

Back to News
Symphogen, a private biopharmaceutical company developing recombinant antibody mixtures, announced today that Genentech, a member of the Roche Group, has dosed for the first time in humans a clinical trial candidate containing a Symplex generated antibody conjugated to an undisclosed active agent.

Chief Executive Officer of Symphogen Kirsten Drejer, PhD stated: “The Genentech collaboration has allowed Symphogen to extend application of our integrated antibody discovery technologies to create value in therapeutic applications outside Symphogen’s oncology focus and we are pleased to see this important compound advance into the clinic’.

For additional information, please contact:

Kirsten Drejer
Chief Executive Officer
Phone:  + 45 22 10 99 59
E-mail: kd@symphogen.com

Gayle Mills
Chief Business Officer
Phone: +1 650 464-3656
E-mail: gmm@symphogen.com

 

Media Inquiries
Heidi K. Roennest
Executive Office Manager
+45 4526 5050
hkr@symphogen.com

About Symphogen
Symphogen is a private biopharmaceutical company leading the field of recombinant antibody mixtures for therapeutic use in oncology. Symphogen is dedicated to bringing truly innovative oncology products to the market, creating optimally selected antibody mixtures that address multiple oncology targets in a single drug product. The company has collaborations for the development of antibody therapeutics in the infectious disease area with Genentech, and in immuno-oncology with Shire. Symphogen has offices in Denmark and New Jersey, US and its investors include Essex Woodlands Health Ventures, Novo A/S, PKA, Sunstone Capital, Gilde Healthcare Partners, Danica Pension, Takeda Ventures, Inc., and Genentech.

Want to know more?